Companies Related to "Study of BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)" [Most Relevant Company Matches] - Page: 20 RSS

18:03 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Study of BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)" found in our extensive corporate database of over 50,000 company records.

Showing "Study BuEAM Conditioning Autologous Stem Cell Transplantation ASCT" Companies 476–500 of 2,100+

Probably Relevant

FirstString Research, Inc.

FirstString Reseach, a clinical stage biotech company, is leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for wound healing, scar reduction, inflammation, and complex tissue regenerationࠀ The company is currently advancing GranexinTM Gel, a topical formulation ...

Saint James School of Medicine

Saint James School of Medicine is an international medical school with two campuses on the Caribbean islands of Anguilla and St. Vincent and the Grenadines. Our students study Basic Sciences at one of our Caribbean campuses then study Clinical Sciences through a clinical rotation program at affiliated hospitals in the US. Saint James School of Medicine was...

Vycellix™, Inc.

Vycellix, Inc., is a closely-held immunotherapy-focused, discovery company with the mission to fundamentally impact the challenges that currently prevail in the area of cell & gene based-therapies. The Company is engaged in the development of proprietary approaches for cell-based immunotherapeutic products and to improve patient outcomes.

TissueTech, Inc.

TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal, and wound care markets. The NIH has supported research by TissueTech with more than 25 continuous years of research grants. Since its inception in 2001, over 200,000 human implants have been conducted using the Company’...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Brain Injury Research Institute

The Brain Injury Research Institute is a center for the study of traumatic brain injuries and prevention, which is affiliated with the Blanchette Rockefeller Neuroscience Institute at West Virginia University. The purpose of the Institute is to study the short and long-term impact of brain injuries in order to better understand the impact of concussions, the development of chronic traumatic enceph...

Unum Therapeutics

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and effi...

The CePower Ltd

The CePower Ltd. was created in spring 2002 and it is located in Wädenswil, Switzerland. The enterprise is a Biotech company and offers services within the field of cell biology. CePower Ltd. is specialzed in serum-free cultivation of mamalian cells. Since existence of the company various cell lines, like for example the HEK-293, CHO, Vero, Sp2/0 and the Ag8 were adapted to serum-free media succe...

Cell Signaling Technology, Inc.

The genomic era has yielded a wealth of new genes for which function and inter-relationships remain unknown. At the same time there is an increasing appreciation of the limits of what can be learned from gene expression profiling, and of the need to examine protein expression and activity. Activation-state-specific antibodies have proven to be a convenient and reliable set of tools in the new post...


Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen®, a ret...

Proneuron Biotechnologies (Israel) Limited

Proneuron Biotechnologies is developing therapies for neurological, ophthalmologic and immune-related disorders such as spinal cord injuries, multiple sclerosis, glaucoma, Parkinson's disease and Alzheimer's diseases. The technology derives from research on key mechanisms in the dialogue between the nervous and immune systems originating from The Weizmann Institute of Science. Proneuron's novel st...

Ysios Capital

Ysios Capital is an independent venture capital firm providing private equity financing to early through late-stage human healthcare and biotechnology companies with special focus on pharmaceuticals, diagnostics and medical devices. Ysios launched its first 69 million Euro fund Ysios BioFund I in 2008. Ysios has invested in 10 companies, and has successful...

Triumvira Immunologics

Triumvira is developing an engineered T-cell technology called the T-Cell Antigen Coupler (TAC), developed in the laboratory of Dr. Jonathan Bramson at McMaster University in Hamilton, Ontario, and is designed to activate T-cells through the T-cell receptor complex. In multiple liquid and solid tumor animal models, TAC-T cells outperform CAR-T cells, with ...

Cell Sciences

Cell Sciences offers immunochemicals for life science research. Recombinant cytokines, cytokine receptors, chemokines, kinases, phosphatases, ELISA and ELISPOT kits, monoclonal and polyclonal antibodies, and matched antibody pairs for do-it-yourself ELISA and ELISPOT assays are available.


Founded in 2015, Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity. Gadeta’s new cell-based anti-cancer product called T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs) has strong therap...

DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry. In addition to the offering of world-class biopharmaceutical manufacturing services, DSM Biologics provides and develops technologies relevant for optimized mammalian cell culture processes. Examples are the proprietary XD® Technology for ...

CrossFit, Inc.

CrossFit, Inc. is the world's foremost developer of functional fitness programming and a leading accredited certificate issuer for physical training professionals worldwide. Founded by Greg and Lauren Glassman, CrossFit® is the principal strength-and-conditioning program for hundreds of accomplished and professional athletes and hundreds of thousands of...

Trevigen Incorporated

Trevigen is a long standing provider of quality kits and reagents for researchers investigating programmed cell death, DNA damage and repair, cell differentiation and angiogenesis. Trevigen recently launched PathClear™ Basement Membrane Extract in the Cultrex® product line." Telephone Toll Free: 1-800-TREVIGEN

NantCell, Inc.

NantCell, an entity controlled by Dr. Patrick Soon-Shiong, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of the patient's tumor, independent of the cancer's anatomical type.

International Association for the Study of Pain

Executive Committee of Beautiful Study

Bowen Center for the Study of the Family

Center for the Study of the Presidency and Congress

European Association for the Study of the Liver

More From BioPortfolio on "Study of BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)"

Quick Search


Corporate Database Quicklinks